NICE Scientific Advice (NSA), working with the NICE Scientific Policy and Research Team, have examined a patient preference study for people with chronic obstructive pulmonary disease (COPD). This is the first time such a study design has been considered by NSA, and is part of a move to encourage companies to seek advice.
Patient preference studies are increasingly common, but NICE believe their quality can be improved by making use of the NSA team, as companies would for other kinds of study design. In this case, Novartis sought scientific advice in order to improve its early evidence generation and support the development of new products for COPD.
Jeanette Kusel, Director of NICE Scientific Advice said:
“We are delighted to be able to shape our offering to suit the requirements of Novartis. Offering advice and guidance on their patient preference study should help it to generate the data required to help future products meet the needs of COPD patients.”
Nigel Cook, Head of Decision Support & Insights, Global Patient Access at Novartis said:
“The scientific advice provided by NICE, together with the patient representative and other external experts, has been very valuable to Novartis; both in endorsing the approach to gathering early patient preference data to inform evidence generation plans, and in regard to valuable input received to improve the design of the COPD patient preference study.
“Collecting certain outcome data alongside the patient preferences, one of the advice recommendations, will also help in correlating the preference results with current NICE processes for evaluating new treatments.
“We see this engagement during the project design phase as a positive step, helping to ensure the results serve the interests of the different stakeholders: industry, NICE and the patient community.”